An Act establishing a commission to study maximum allowable costs lists

HD 2246 establishes a 10-member commission to study how insurance plans and pharmaceutical benefit managers set "maximum allowable costs lists" - tools that define the highest payment amount for prescription drugs. The commission, including government officials and representatives from health plans, pharmacists, drug companies, and pharmacy benefit managers, will examine current practices, financial impacts, and transparency around these lists. It must submit a report and any proposed legislation to state committees within 180 days of the bill's passage. This bill creates a review process but does not change existing drug payment rules.